Dermatopathologists throughout the country have experienced the value myPath® Melanoma adds to the diagnosis of challenging melanocytic lesions through their participation in the melEvalPRO clinical experience program.

As part of their participation in this program, dermatopathologists completed a series of survey questions each time they prospectively submitted a melanocytic lesion for myPath Melanoma testing.

Survey completed at the time of sample submission.

Pre-Test Survey

myPath Melanoma Testing

Score is calculated and the test result is reported to the physician.

Survey completed after result is reported to physician.

Post-Test Survey

Surveys were completed at the time of sample submission and after myPath Melanoma results were reported to the dermatopathologist.

The ordering physician provided information regarding:

  1. Favored pre- and post-test diagnoses and differential diagnoses
  2. Level of confidence in the favored diagnosis
  3. Pre- and post-test recommendations for treatment of the melanocytic lesion

Answers were analyzed to measure the impact of testing on the dermatopathologist’s diagnosis and treatment recommendations.

After the myPath Melanoma score was reported to the dermatopathologist, post-test survey results showed a 53% increase in definitive diagnoses (benign or malignant) for those patients who would have otherwise received an indeterminate diagnosis of their melanocytic lesion based on histopathologic interpretation alone.

The test has been shown to increase Diagnostic Confidence

Cases when a myPath Melanoma test was performed

Increase in definitive diagnoses

Revised Treatment Recommendations*

Actual Treatment Revised

In addition, treatment recommendations were revised by dermatopathologists in 49% of histopatholoigcally ambiguous* cases. These changes tended to align with the myPath Melanoma score, where 39.4% of cases receiving a benign score were downgraded to less invasive treatment recommendations and 45.8% of cases receiving a malignant result were upgraded to more invasive recommendations.

Preliminary data suggests the actual treatment provided to the patient by the clinician was revised in as many as 64% of cases when a myPath Melanoma test was performed by the dermatopathologist.

*Histopathologically ambiguous cases were defined as those cases submitted with a pre-test diagnosis of indeterminate, or a pre-test diagnosis of benign or malignant where the dermatopathologist had low diagnostic confidence.

These data demonstrate the clinical utility of myPath Melanoma through the impact of test results on diagnostic decision-making and treatment recommendations among dermatopathologists assessing histopatholoigcally ambiguous melanocytic lesions.

Complete results of this clinical utility analysis are published in Medicine and were presented at the 2015 annual meeting of the American Academy of Dermatology. 8, 28